.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Sumatriptan - Generic Drug Details

« Back to Dashboard
Sumatriptan is the generic ingredient in nine branded drugs marketed by Glaxosmithkline, Lannett, Teva Pharms Usa, Injectalia, Sagent Strides, Teva Parenteral, Antares Pharma Inc, Mylan Labs Ltd, Eurohlth Intl Sarl, Dr Reddys Labs Ltd, Aurobindo Pharma, Par Pharm, Watson Labs, Endo Ventures Ltd, Fresenius Kabi Usa, Teva, Sagent Agila, Roxane, Mylan, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Aurobindo Pharma Ltd, Sun Pharma Global, Apotex Inc, Sandoz, Par Sterile Products, Meridian Medcl, Teva Branded Pharm, Hikma Farmaceutica, Orchid Hlthcare, Wockhardt, Sun Pharm Inds, Hikma Pharms, and Avanir Pharms, and is included in forty-one NDAs. There are thirty-eight patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twenty-three drug master file entries for sumatriptan. Four suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for Generic Name: sumatriptan

Tradenames:9
Patents:38
Applicants:34
NDAs:41
Drug Master File Entries: see list23
Suppliers / Packaging: see list4
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Tentative approvals for SUMATRIPTAN

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL25MG
<disabled><disabled>TABLET; ORAL50MG
<disabled><disabled>TABLET; ORAL100MG
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
IMITREX
sumatriptan succinate
TABLET;ORAL020132-002Jun 1, 1995RXNo► subscribe► subscribe
Avanir Pharms
ONZETRA XSAIL
sumatriptan succinate
POWDER;INHALATION206099-001Jan 27, 2016RXYes8,555,877► subscribeY ► subscribe
Teva Branded Pharm
ZECUITY
sumatriptan succinate
SYSTEM;IONTOPHORESIS202278-001Jan 17, 2013RXYes► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: sumatriptan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-003Aug 26, 19974,816,470*PED► subscribe
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-003Aug 26, 19975,705,520*PED► subscribe
Glaxosmithkline
IMITREX
sumatriptan
SPRAY;NASAL020626-001Aug 26, 19974,816,470*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc